EGF and asthma: We suggest that further in vitro studies with a larger cohort of asthmatic children using the ALI model of bronchial epithelium would be the next step in determining whether EGF inhibitors, such as AG1478, could be considered as a viable therapeutic for reducing goblet cell hyperplasia and mucus hypersecretion in asthma.